Premium
Allogeneic peripheral blood stem cell transplantation in acute non‐lymphoblastic leukemia
Author(s) -
Arslan Önder,
Üstün Celalettin,
Arat Mutlu,
Çelebi Harika,
Akan Hamdi,
Beksaç Meral,
Ilhan Osman,
Gürman Günhan,
Özcan Muhit,
Konuk Nahide,
Uysal Akin,
Koç Haluk
Publication year - 1998
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/(sici)1099-1069(199812)16:4<155::aid-hon633>3.0.co;2-0
Subject(s) - lymphoblastic leukemia , peripheral blood , medicine , stem cell , transplantation , peripheral blood stem cells , immunology , leukemia , peripheral , cancer research , hematopoietic stem cell transplantation , biology , microbiology and biotechnology
Unmodified allogeneic peripheral blood stem cell transplantation (alloPBSCT) was performed in 20 consecutive acute non‐lymphoblastic leukemia (ANLL) patients from their HLA‐identical siblings. There were 11 males and 9 females. Median age was 34 years (range 17–43). Donors were primed with 2·5–15 μg/kg/day s.c. granulocyte‐colony stimulating factor (G‐CSF, Neupogen, Roche). Conditioning regimen was Bu (16 mg/kg)+Cy (120 mg/kg) in 19 patients and high dose Ara‐C (3 gr/m 2 twice daily for 3 days) for one patient who relapsed after bone marrow transplantation. Eighteen patients were in CR1. CsA+short‐term MTX ( n =19) or CsA alone ( n =1) were used for graft versus host disease (GVHD) prophylaxis. The median number of apheresis procedures for each patient was 2 (2–4). A median of 6·5 (3·2–38·2)×10 8 /kg MNC or 9·4 (2·2–12·4)×10 6 /kg CD34+cells were given. Median days to reach granulocyte of >0·5×10 9 /l and platelet of >50×10 9 /l were 12 (10–14) and 15 (11–35) respectively. Day 100 transplant‐related mortality was 20 per cent (4/20). Grade 2 to 4 AGVHD was seen in 8 out of 17 (47%) evaluable patients. Severe AGVHD occurred in 3 out of 17 (18%). Clinical CGVHD of all grades developed in 12 out of 17 (70%) evaluable patients. The mean disease‐free survival and overall survival were 17 (range: 8–33 months) and 18 months (range: 10–34 months), respectively. In conclusion, alloPBSCT in ANLL is associated with a faster engraftment, no greater incidence of AGVHD, but increased risk of CGVHD. Copyright © 1998 John Wiley & Sons, Ltd.